Target Product Profile for
Visceral Leishmaniasis

 

As a prerequisite to building the strategy, the target product (treatment) profile (TPP) has been established. It is based on discussions with various VL experts, consultation with VL national control programmes in endemic countries, and specifically with leading physicians and health workers who deal with this disease on a daily basis. Our TPP is reviewed and revised annually, and shared with other investigators openly.

The priority is to develop a safe, effective, oral, short-course (11 days maximum) visceral leishmaniasis drug to replace current treatments. This will improve and simplify current case management. The aim is to develop combinations of drugs that are effective against visceral leishmaniasis in all foci of the disease.

Read more

Target Product Profile for
Cutaneous Leishmaniasis

 

A target product profile (TPP) for cutaneous leishmaniasis (CL) has been developed in consultations with CL experts, researchers and clinicians from both Old and New World. The TPP is being been reviewed and updated on regular bases and has been approved by the R&D team and SAC.

The main goal of the cutaneous leishmaniasis program at DNDi is to achieve short duration, safe, non-invasive, efficacious, affordable and field-friendly treatments for CL caused by L.tropica and L. braziliensis.

Read more